ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

J. U. Holle*, W. L. Gross

*Corresponding author for this work
17 Citations (Scopus)


A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review.

Original languageEnglish
JournalJournal of Autoimmunity
Issue number3-4
Pages (from-to)163-171
Number of pages9
Publication statusPublished - 05.2009

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy'. Together they form a unique fingerprint.

Cite this